Domov › Trojno negativni rak dojke › Texas › San Antonio
Klinične študije za Trojno negativni rak dojke v San Antonio, TX
23 študij za Trojno negativni rak dojke išče udeležence na lokacijah v San Antonio in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Vključevanje udeležencevFaza 1
- South Texas Accelerated Research Therapeutics (START), San Antonio
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Vključevanje udeležencevFaza 1/2
- New Experimental Therapeutics of San Antonio - NEXT Oncology, San Antonio
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Vključevanje udeležencevFaza 1/2
- NEXT Oncology, San Antonio
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Vključevanje udeležencevFaza 3
- Texas Oncology - San Antonio ( Site 8001), San Antonio
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Vključevanje udeležencevFaza 3
- Mays Cancer Center ( Site 0122), San Antonio
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Vključevanje udeležencevFaza 3
- Texas Oncology - San Antonio ( Site 8004), San Antonio
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
Vključevanje udeležencevFaza 1
- NEXT Oncology, San Antonio
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- NEXT Oncology - San Antonio, San Antonio
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Vključevanje udeležencevFaza 3
- Texas Oncology, San Antonio
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Vključevanje udeležencevFaza 1
- South Texas Accelerated Research Therapeutics (START) San Antonio, San Antonio
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Vključevanje udeležencevFaza 1
- START-San Antonio, San Antonio
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Vključevanje udeležencevFaza 1/2
- Research Site, San Antonio
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Vključevanje udeležencevFaza 1
- Normunity Investigational Site, San Antonio
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- START San Antonio, San Antonio
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- Clinical Trial Site, San Antonio
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- NEXT Virginia, LLC, San Antonio
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Vključevanje udeležencevFaza 1
- START San Antonio, San Antonio
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Vključevanje udeležencevFaza 1
- NEXT Oncology /ID# 243007, San Antonio
- South Texas Accelerated Research Therapeutics (START) /ID# 276268, San Antonio
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Vključevanje udeležencevFaza 1
- NEXT Texas LLC - San Antonio, San Antonio
- START San Antonio, LLC, San Antonio
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- NEXT Oncology, San Antonio
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
Vključevanje udeležencevFaza 1
- NEXT Oncology, San Antonio
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Vključevanje udeležencevFaza 1
- Dren Investigational Site, San Antonio
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Vključevanje udeležencevFaza 2
- Texas Oncology PA (San Antonio), San Antonio
Študije za Trojno negativni rak dojke v drugih mestih
- Houston, TX42 študij
- New York City, NY31 študij
- Nashville, TN28 študij
- Los Angeles, CA27 študij
- Boston, MA26 študij
- St. Louis, MO21 študij
- Arlington, VA20 študij
- Atlanta, GA20 študij
- Dallas, TX18 študij
- Chicago, IL16 študij
- Columbus, OH16 študij
- Grand Rapids, MI15 študij
Druge študije v San Antonio
- Nemalicelični pljučni rak59 študij
- Rak dojke47 študij
- Kolorektalni rak46 študij
- Metastatski rak44 študij
- Rak (vse vrste)41 študij
- Debelost40 študij
- Sladkorna bolezen tipa 237 študij
- Prekomerna telesna teža34 študij
- Rak jajčnikov31 študij
- Rak trebušne slinavke31 študij
- Rak prostate28 študij
- Rak endometrija27 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.